Diamonds and Dogs


Turning Point Therapeutics (TPTX) jumps 116% after agreeing to a $4.1 billion offer from Bristol Myers Squibb (BMY). The deal adds repotrectinib to Bristol Myers' wheelhouse. Repotrectinib is a potential treatment for lung cancer patients with a specific genetic mutation. It's expected to launch next year.Wedbush analyst David Nierengarten says the deal could be a positive for the broader cancer space and for similar small/mid-cap biotechs

Elon Musk has a "super bad feeling" about the economy. Tesla, the world's most valuable auto maker, is down 8% after their CEO made cautious comments on the economy and indications the company may cut staff by 10%. 

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.